Post-tonsillectomy hemorrhage (PTH) is a high-stakes pediatric emergency. Bleeding can be brisk, difficult to quantify, and rapidly compromise the airway. Nebulized tranexamic acid (TXA) is a promising, increasingly used ED adjunct – but it is not definitive management.
1. Don’t be reassured by a child who looks well
Children may swallow substantial amounts of blood before presenting, making blood loss difficult to estimate. Hematemesis, melena, pallor, tachycardia, or recurrent bleeding should raise concern even when the child initially appears comfortable.
Start with the basics:
- Keep the child upright and leaning forward.
- Have suction immediately available.
- Keep the patient NPO and obtain IV access.
- Assess hemodynamics in all patients. For significant or ongoing bleeding, obtain a CBC and a type and screen. Remember that the initial hemoglobin may not reflect the magnitude of acute blood loss.
- Involve ENT early and prepare for resuscitation and possible airway or operative intervention; if definitive care is unavailable, initiate prompt transfer while continuing resuscitative measures.
Avoid blind or traumatic manipulation of the tonsillar fossa, which can disrupt an evolving clot.
Clinical pearl: Active PTH is an airway and hemorrhage emergency. TXA should never delay airway management, resuscitation, ENT involvement, or definitive hemostasis.
2. Nebulized TXA may help control bleeding and buy you time
TXA inhibits fibrinolysis and may stabilize clot formation. Nebulized delivery is appealing because it provides a noninvasive way to treat the bleeding oropharyngeal surface. Published regimens vary. In one large mixed-age cohort, patients typically received a single 500 mg/5 mL nebulized dose, while pediatric protocols may use weight-based dosing and repeat treatments. Clinicians should follow local ENT and pharmacy guidance.
In a 2025 retrospective study of 287 children with PTH, surgical control was required in 26.0% of patients receiving nebulized TXA versus 41.7% without TXA. After adjustment for active bleeding and the presence of a clot on examination, TXA was associated with lower odds of surgery (adjusted OR 0.25, 95% CI 0.13–0.48) – roughly 75% lower adjusted odds, not a 75% reduction in absolute risk. Readmission for rebleeding did not differ significantly (9.0% versus 7.0%), and no TXA-attributable complications were reported.
A 2026 systematic review and meta-analysis of eight pediatric studies involving 801 children found that TXA was associated with a lower risk of reoperation for hemostasis (pooled RR 0.62, 95% CI 0.49–0.78), with no significant difference between intravenous and nebulized administration. However, the included evidence was limited by retrospective designs, small samples, and risk of bias.
Clinical pearl: TXA can stop the bleeding without solving the problem.
3. TXA is an adjunct – not a substitute for definitive management
The current evidence is mostly retrospective cohorts, case series, and quality-improvement studies. None can prove that TXA itself caused the reduction in surgery rates.
A child who improves after TXA can still rebleed. Decisions about observation, admission, transfusion, and operative management should depend on the examination, bleeding history, airway status, and hemodynamics, not simply on the response to TXA.
Under a defined institutional pathway and after ENT evaluation, selective observation may be appropriate for stable children with a visible clot but no active bleeding. At one center, implementation of this approach was associated with a reduction in operative intervention from 54.65% to 26.87%, without a statistically significant increase in revisits requiring surgery or multiple operations.
Clinical pearl: Improvement after TXA is a window to reassess – not a reason to stop.
The Bottom Line
Airway, resuscitation, suction, & ENT come first. TXA is a bridge to those things, never a replacement for them.
Nebulized TXA may help control bleeding and reduce the need for operative intervention, but no universal regimen or disposition pathway exists. Use it to buy time – not to talk yourself out of calling ENT.
References
Postoperative Tonsillectomy Hemorrhage. Emergency Medicine Clinics of North America, 2018.
Nebulized Tranexamic Acid for the Control of Pediatric Post-tonsillectomy Hemorrhage. International Journal of Pediatric Otorhinolaryngology, 2025.
Post-tonsillectomy hemorrhage control with nebulized tranexamic acid: A retrospective cohort study. International Journal of Pediatric Otorhinolaryngology, 2021.
Treatment of post-tonsillectomy hemorrhage with nebulized tranexamic acid: A retrospective study. International Journal of Pediatric Otorhinolaryngology, 2023.
Analysis of an Observational Versus Surgical Approach for Pediatric Post-Tonsillectomy Hemorrhage. The Laryngoscope, 2026.
The Effectiveness of Tranexamic Acid in Pediatric Posttonsillectomy Hemorrhage (A Systematic Review and Meta-Analysis). Otolaryngology–Head and Neck Surgery, 2026.
Dr. Anum N. Mitha, D.O., is a second-year Pediatric Emergency Medicine fellow at Maimonides Medical Center in Brooklyn, New York. She can be reached at amitha@maimo.org.
If I remember correctly, the literature also supports its use in preventing rebleeds. Because of this, if there was any concern in a post T&A bleed, but they are no longer bleeding, I still give it.